1 -- 1 of 33 -- 4th Quarter 2021 Earnings Call January 25, 2022 -- 2 of 33 -- Cautionary Note on Forward-looking Statements This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, market position, business strategy, and the anticipated separation of the Company’s Consumer Health business. The viewer is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: risks related to the impact of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays and cancellations of medical procedures, supply chain disruptions and other impacts to the business, or on the Company’s ability to execute business continuity plans, as a result of the COVID-19 pandemic; economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies; the Company’s ability to satisfy the necessary conditions to consummate the separation of the Company’s Consumer Health business on a timely basis or at all; the Company’s ability to successfully separate the Company’s Consumer Health business and realize the anticipated benefits from the separation; and the New Consumer Health Company’s ability to succeed as a standalone publicly traded company. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2021 including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in the Company’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this presentation speaks only as of the date of this presentation. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. Cautionary Note on Non-GAAP Financial Measures This presentation refers to certain non-GAAP financial measures. These non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the Company’s website at www.investor.jnj.com. 3 -- 3 of 33 -- Immunology REMICADE and SIMPONI/ SIMPONI ARIA marketing partners are Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation; TREMFYA discovered using MorphoSys AG antibody technology Neuroscience INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA/ INVEGA HAFYERA are subject to a technology license agreement from Alkermes Pharma Ireland Limited, and RISPERDAL CONSTA developed in collaboration with Alkermes, Inc. Infectious Diseases PREZCOBIX / REZOLSTA fixed-dose combination, SYMTUZA and ODEFSEY developed in collaboration with Gilead Sciences, Inc., and JULUCA and CABENUVA developed in collaboration with ViiV Healthcare UK. Research and development activities for the Company’s COVID-19 vaccine, including the ENSEMBLE clinical trial and the delivery of doses for the U.S., have been funded in part with federal funds from the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA), under Contract No. HHSO100201700018C, and in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) at the U.S. Department of Health and Human Services (HHS) Cardiovascular/ Metabolism/Other INVOKANA/ INVOKAMET/ VOKANAMET/ INVOKAMET XR fixed-dose combination licensed from Mitsubishi Tanabe Pharma Corporation; XARELTO co-developed with Bayer HealthCare AG; PROCRIT/ EPREX licensed from Amgen Inc., and X-Linked Retinitis Pigmentosa: AAV-RPGR licensed from MeiraGTx Oncology IMBRUVICA developed in collaboration and co-marketed in the U.S. with Pharmacyclics, LLC, an AbbVie company; ZYTIGA licensed from BTG International Ltd.; VELCADE developed in collaboration with Millennium: The Takeda Oncology Company; DARZALEX and DARZALEX FASPRO licensed from Genmab A/S, BALVERSA licensed and discovered in collaboration with Astex Pharmaceuticals, Inc.; ERLEADA licensed from Regents of California and Memorial Sloan Kettering; cilta-cel licensed and developed in collaboration with Legend Biotech USA Inc. and Legend Biotech Ireland Limited, niraparib licensed from TESARO, Inc., an oncology-focused business within GSK, lazertinib licensed from Yuhan Corporation, DuoBody platform licensed from Genmab A/S relates to several bispecific antibody programs, ENHANZE platform licensed from Halozyme Therapeutics, Inc. Pulmonary Hypertension UPTRAVI license and supply agreement with Nippon Shinyaku (co-promotion in Japan), and OPSUMIT co-promotion agreement with Nippon Shinyaku in Japan Global Public Health Janssen’s Monovalent Ebola Vaccine is developed in collaboration with Bavarian Nordic A/S, and MVA-BN-Filo® is licensed-in from Bavarian Nordic A/S. The program has benefited from funding and preclinical services from the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, NIAID support included 2 product development contracts starting in 2008 and 8 pre-clinical services contracts. This program is also receiving funding from the IMI2 Joint Undertaking under EBOVAC1 (grant nr. 115854), EBOVAC2 (grant nr. 115861), EBOVAC3 (grant nr. 800176), EBOMAN (grant nr. 115850) and EBODAC (grant nr. 115847). The IMI2 Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). Further funding for the Ebola vaccine regimen has been provided by BARDA, within the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response, under Contract Numbers HHSO100201700013C and HHSO100201500008C.. The initial work on Ebola was conducted which was extended from 2002 until 2011. 2002 and 2007 via a Cooperative Research and Development Agreement (CRADA is AI-0114) between Janssen/Crucell and the Vaccine Research Center (VRC)/NIAID, part of the NIH. Janssen/Crucell have licenses to much of VRC’s Ebola IP specific for human adenovirus under the Ad26/Ad35 Ebola vaccine CRADA invention. VAC69120 (Filovirus multivalent vaccine) developed in collaboration with Bavarian Nordic; funding: NIH Division of Microbiology and Infectious Diseases (DMID), under Contract Number HHSN272200800056C. Strategic Partnerships, Collaborations & Licensing Arrangements 4 During the course of this morning’s presentation, we will discuss a number of products and compounds developed in collaboration with strategic partners or licensed from other companies. The following is an acknowledgement of those relationships: -- 4 of 33 -- Enterprise Highlights Sales Performance and Earnings Review Capital Allocation and Guidance CEO Remarks Q&A Agenda 1 2 3 4 Joseph J. Wolk Executive Vice President, Chief Financial Officer Jessica Moore Vice President, Investor Relations Joaquin Duato Chief Executive Officer 5 5 -- 5 of 33 -- Regional Sales Results Q4 2021 Q4 2020 % CHANGE Reported Operational1 U.S. $12.2 $11.8 3.0% 3.0% Europe 6.9 5.3 31.4 34.7 Western Hemisphere (ex U.S.) 1.5 1.4 3.9 5.0 Asia-Pacific, Africa 4.3 4.0 6.6 9.0 International 12.6 10.7 18.5 21.2 Worldwide (WW) $24.8 $22.5 10.4% 11.6% 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website Note: Values may not add due to rounding 4th Quarter 2021 Sales Dollars in Billions 6 -- 6 of 33 -- 14.5%; 17.2%1 Q4 2021 Q4 2020 $2.13 $1.86 4th Quarter 2021 Financial Highlights Dollars in Billions, except EPS Reported %; Operational %1 7 Sales Adjusted Earnings2 Adjusted EPS2 10.4%; 11.6%1 $24.8 $22.5 GAAP Earnings 172.5% $4.7 $1.7 14.4% Q4 2021 Q4 2020 GAAP EPS 172.3% $1.77 $0.65 Q4 2021 Q4 2021 Q4 2020 Q4 2020 Q4 2021 Q4 2020 $5.7 $5.0 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website 2 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules in the Investors section of the company's website -- 7 of 33 -- Regional Sales Results 2021 2020 % CHANGE Reported Operational1 U.S. $47.2 $43.1 9.3% 9.3% Europe 23.6 19.0 24.3 20.7 Western Hemisphere (ex U.S.) 5.8 5.3 7.8 7.3 Asia-Pacific, Africa 17.3 15.1 14.1 11.4 International 46.6 39.5 18.2 15.3 Worldwide (WW) $93.8 $82.6 13.6% 12.2% 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website Note: Values may not add due to rounding Full Year 2021 Sales Dollars in Billions 8 -- 8 of 33 -- 22.0%; 20.2%1 2021 2020 $9.80 $8.03 Full Year 2021 Financial Highlights Dollars in Billions, except EPS Reported %; Operational %1 9 Sales Adjusted Earnings2 Adjusted EPS2 13.6%; 12.2%1 $93.8 $82.6 GAAP Earnings 41.9% $20.9 $14.7 22.2% 2021 2020 GAAP EPS 41.7% $7.81 $5.51 2021 2021 2020 2020 2021 2020 $26.2 $21.4 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website 2 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules in the Investors section of the company's website -- 9 of 33 -- OTC $1,373 Skin Health/Beauty $1,084 Oral Care $405 Baby Care $399 Women's Health $233 Wound Care/Other $164 $3,657 1.1%, 1.8% WW Sales $MM ■ Reported Growth ■ Operational Growth1 Consumer Health Highlights – 4th Quarter 2021 Solid adjusted operational growth2 driven by OTC 10 Key Drivers of Operational Performance1 OTC • Growth driven by increased U.S. adult and pediatric fever incidences (TYLENOL, MOTRIN) and WW category recovery for Cough, Cold, & Flu and Digestive Health, as well as U.S. share gains across multiple brands (TYLENOL, MOTRIN) partially offset by lapping prior year additional shipping days Skin Health/ Beauty • Decline driven by DR. CI LABO - Sedona divestiture in ASPAC, lapping prior year additional shipping days, and U.S. external supply constraints partially offset by WW COVID-19 recovery and e-commerce strength Oral Care • Decline driven by lapping prior year additional shipping days, floss divestiture and category declines in EMEA partially offset by successful brand building and promotional campaigns in ASPAC Baby Care • Decline driven by lapping prior year additional shipping days and retailer stocking, coupled with U.S. external supply constraints partially offset by AVEENO Baby strength primarily due to ASPAC e-commerce growth Women’s Health • Growth driven by COVID-19 market recovery in LATAM partially offset by lapping prior year additional shipping days Wound Care/Other • Decline driven by lapping prior year additional shipping days and professional tape divestiture, along with product discontinuations in ASPAC partially offset by U.S. category growth and U.S. strength in BAND-AID® Brand Adhesive Bandages Adjusted Operational Sales2: WW 2.9%, U.S. 1.9%, Int’l 3.6% Additional 2020 shipping days negatively impacted WW growth by ~4% Reported: WW 1.1%, U.S. 1.3%, Int’l 0.9% Operational1: WW 1.8%, U.S. 1.3%, Int’l 2.1% 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website 2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website Note: Values may not add due to rounding 15.9%, 15.8% (1.6)%, 1.3% (6.2)%, (6.4)% (2.0)%, (0.8)% (7.6)%, (6.5)% (8.0)%, (7.1)% -- 10 of 33 -- Key Drivers of Operational Performance1 Immunology • Growth driven by continued strong uptake of STELARA in Crohn’s Disease and Ulcerative Colitis, partially offset by negative U.S. prior period rebate adjustment and reserve adjustment • Strength in TREMFYA in Psoriasis and uptake in Psoriatic Arthritis • REMICADE decline due to biosimilar competition Infectious Diseases • Growth driven by the contribution of the COVID-19 vaccine • Partially offset by increased competition for PREZISTA/PREZCOBIX/REZOLSTA and PREZISTA OUS LOE Neuroscience • Paliperidone long-acting injectables growth due to strength of INVEGA SUSTENNA/XEPLION and INVEGA TRINZA/TREVICTA from new patient starts and persistency, as well as the launch of INVEGA HAFYERA Oncology • DARZALEX increase driven by continued strong market growth and share gains in all regions and solid uptake of the subcutaneous formulation launched in 2020 • Continued strong global launch uptake of ERLEADA • IMBRUVICA maintained its market leadership but declined worldwide due to competitive pressures from novel oral agents. U.S. decline partially offset by growth in all regions outside of the U.S. Cardiovascular/ Metabolism/ Other (CVM/Other) • Decline driven by lower sales of PROCRIT/EPREX due to biosimilar competition • INVOKANA/INVOKAMET decline due to continued share erosion Pulmonary Hypertension (PH) • Portfolio was roughly flat due to COVID-19 related market restraints and generic entrants in Other Pulmonary Hypertension offset by U.S. share uptake in both OPSUMIT and UPTRAVI Adjusted Operational Sales2: WW 18.6%, U.S. 4.2%, Int’l 38.6% Additional 2020 shipping days negatively impacted WW growth by ~4% Immunology $4,355 Infectious Diseases $2,437 Neuroscience $1,793 Oncology $3,778 CVM/Other $1,074 PH $851 $14,288 16.5%, 17.9% WW Sales $MM ■ Reported Growth ■ Operational Growth1 Pharmaceutical Highlights – 4th Quarter 2021 11 Reported: WW 16.5%, U.S. 4.2%, Int’l 33.4% Operational1: WW 17.9%, U.S. 4.2%, Int’l 36.9% 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website 2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website Note: Values may not add due to rounding (14.3)%, (13.8)% (1.6)%, (0.2)% 10.0%, 12.3% 5.5%, 7.1% 167.3%, 168.8% 6.1%, 7.1% Continued above-market performance driven by Oncology, Immunology, and Neuroscience -- 11 of 33 -- Orthopaedics $2,155 Surgery $2,513 Vision $1,171 Interventional Solutions $1,019 $6,859 4.1%, 5.3% WW Sales $MM ■ Reported Growth ■ Operational Growth1 Medical Devices Highlights – 4th Quarter 2021 Growth primarily driven by COVID-19 market recovery, commercial initiatives, and innovation 12 Reported: WW 4.1%, U.S. 1.0%, Int’l 7.0% Operational1: WW 5.3%, U.S. 1.0%, Int’l 9.3% Key Drivers of Operational Performance1 Interventional Solutions • Market recovery, success of new products (VIZIGO and CARTO V7) and commercial strategies continuing to enhance global leadership Orthopaedics • Hips: Growth reflects market recovery combined with continued strength of our portfolio including the ACTIS stem and enabling technologies – KINCISE and VELYS Hip Navigation • Trauma: Growth reflects global market recovery and uptake of new products including Cannulated Compression Headless Screws, Advanced Nailing Systems and FIBULINK • Knees: Flat reflecting variability in regional procedure recovery due to COVID-19, channel mix and the positive impact of new products • Spine, Sports & Other: Decline driven primarily by COVID-19 related impacts on the market partially offset by new products (X-PAC, CONDUIT and SYMPHONY) and inventory fluctuations in ASPAC • Spine: WW: ~(9%), U.S.: ~(15%), OUS Flat Surgery • Advanced: • Endocutters: ~+2% Driven by market recovery, new products (ECHELON Staple Line Reinforcement) and market expansion offsetting competitive pressure in the U.S. • Biosurgery: ~+10% Market recovery and share momentum driven by success of newer products (VISTASEAL and SURGICEL POWDER) and ASPAC market expansion • Energy: ~+10% Primarily due to market recovery, new products (ENSEAL X1) and market expansion offsetting competitive pressures in the U.S. • General: Growth primarily driven by market recovery and continued strength of the Suture portfolio Vision • Contact Lenses/Other: Growth driven primarily by market recovery, new products (ACUVUE OASYS Multifocal and ACUVUE DEFINE Fresh) and stocking fluctuations in the U.S. • Surgical: Growth primarily due to market recovery and market share momentum driven by uptake of recently launched products (TECNIS EYHANCE and TECNIS SYNERGY) Adjusted Operational Sales2: WW 5.6%, U.S. 1.2%, Int’l 9.8% Additional 2020 shipping days negatively impacted WW growth by ~4% 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website 2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website Note: Values may not add due to rounding; Beginning in the fiscal first quarter of 2022, the Medical Devices segment will be referred to as the MedTech segment 14.1%, 15.3% 8.7%, 11.0% (1.6)%, (0.7)% 3.5%, 4.4% -- 12 of 33 -- 2021 2020 % Increase (Decrease) Amount % to Sales Amount % to Sales Sales to customers $24,804 100.0 $22,475 100.0 10.4 Cost of products sold 7,955 32.1 7,814 34.8 1.8 Gross Profit 16,849 67.9 14,661 65.2 14.9 Selling, marketing and administrative expenses 7,154 28.9 6,457 28.7 10.8 Research and development expense 4,720 19.0 4,032 17.9 17.1 In-process research and development 0 0.0 37 0.2 Interest (income) expense, net 47 0.2 74 0.3 Other (income) expense, net 9 0.0 2,354 10.5 Restructuring 83 0.3 60 0.3 Earnings before provision for taxes on income 4,836 19.5 1,647 7.3 193.6 Provision for/(Benefit from) taxes on income 100 0.4 (91) (0.4) (209.9) Net Earnings $4,736 19.1 $1,738 7.7 172.5 - Net earnings per share (Diluted) $1.77 $0.65 172.3 Average shares outstanding (Diluted) 2,670.2 2,669.2 Effective tax rate 2.1% (5.5)% . Adjusted earnings before provision for taxes and net earnings1 Earnings before provision for taxes on income $6,339 25.6 $5,601 24.9 13.2 Net earnings $5,678 22.9 $4,965 22.1 14.4 Net earnings per share (Diluted) $2.13 $1.86 14.5 Effective tax rate 10.4% 11.4% Condensed Consolidated Statement of Earnings 1 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules in the Investors section of the company's website 13 4th Quarter 2021 (Unaudited; Dollar and Shares in Millions Except Per Share Figures) -- 13 of 33 -- Adjusted Income Before Tax by Segment1 4th Quarter 2021 14 Pharmaceutical Medical Devices Consumer Health Expenses Not Allocated to Segments 4Q 2021 4Q 2020 Pharmaceutical 34.0% 32.9% Medical Devices 18.1% 16.5% Consumer Health 17.9% 22.5% Total 25.6% 24.9% % to Sales $5.3 $0.9 $5.7 $1.7 $1.3 2021 2020 ($0.3) ($0.4) $5.6B $4.0 $0.8 $6.3B $4.9 $1.2 $0.6 2 $1.1 1 Non-GAAP measure; excludes amortization expense and special items; see reconciliation schedules in the Investors section of the company's website 2 Estimated as of 1/25/2022 -- 14 of 33 -- 2021 2020 % Increase (Decrease) Amount % to Sales Amount % to Sales Sales to customers $93,775 100.0 $82,584 100.0 13.6 Cost of products sold 29,855 31.8 28,427 34.4 5.0 Gross Profit 63,920 68.2 54,157 65.6 18.0 Selling, marketing and administrative expenses 24,659 26.3 22,084 26.8 11.7 Research and development expense 14,714 15.7 12,159 14.7 21.0 In-process research and development 900 1.0 181 0.2 Interest (income) expense, net 130 0.1 90 0.1 Other (income) expense, net 489 0.5 2,899 3.5 Restructuring 252 0.3 247 0.3 Earnings before provision for taxes on income 22,776 24.3 16,497 20.0 38.1 Provision for taxes on income 1,898 2.0 1,783 2.2 6.4 Net Earnings $20,878 22.3 $14,714 17.8 41.9 - Net earnings per share (Diluted) $7.81 $5.51 41.7 Average shares outstanding (Diluted) 2,674.0 2,670.7 Effective tax rate 8.3% 10.8% . Adjusted earnings before provision for taxes and net earnings1 Earnings before provision for taxes on income $30,464 32.5 $25,428 30.8 19.8 Net earnings $26,195 27.9 $21,433 26.0 22.2 Net earnings per share (Diluted) $9.80 $8.03 22.0 Effective tax rate 14.0% 15.7% Condensed Consolidated Statement of Earnings 1 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules in the Investors section of the company's website 15 Full Year 2021 (Unaudited; Dollar and Shares in Millions Except Per Share Figures) -- 15 of 33 -- Adjusted Income Before Tax by Segment1 Full Year 2021 16 Pharmaceutical Medical Devices Consumer Health Expenses Not Allocated to Segments 2021 2020 Pharmaceutical 40.5% 42.0% Medical Devices 25.7% 17.0% Consumer Health 23.8% 23.8% Total 32.5% 30.8% % to Sales 2021 2020 ($1.1) ($0.9) $25.4B $19.1 $3.9 $3.3 $30.5B $21.1 $7.0 $3.5 2 1 Non-GAAP measure; excludes amortization expense and special items; see reconciliation schedules in the Investors section of the company's website 2 Estimated as of 1/25/2022 -- 16 of 33 -- Notable New Announcements in 4th Quarter 20211 Pharmaceutical • Regulatory Decisions: – European Commission Approves BYANNLI® (6-monthly Paliperidone Palmitate; PP6M) for the Maintenance Treatment of Schizophrenia in Adults – U.S. FDA Approves DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in Combination with Carfilzomib and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse – Janssen EMEA Receives Conditional Marketing Authorisation for RYBREVANT® (amivantamab), the First Treatment Approved for Patients with Advanced NonSmall Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutations After Failure of Platinum-Based Therapy – Johnson & Johnson COVID-19 Vaccine Booster Shot Authorized for Emergency Use by U.S. FDA – World Health Organization Strategic Advisory Group of Experts (SAGE) Interim Recommendation Supports Use of Johnson & Johnson COVID-19 Vaccine as a Booster – Johnson & Johnson Announces Positive CHMP Opinion for a Booster Shot of its COVID-19 Vaccine – FDA Approves Two New Indications for XARELTO® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients • Regulatory Submission: – Janssen Seeks Approval of IMBRUVICA® (ibrutinib) in a Fixed-Duration Regimen for Patients with Untreated Chronic Lymphocytic Leukaemia (CLL) (EU) – Janssen Submits Biologics License Application to U.S. FDA Seeking Approval of Teclistamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma • Other: – Johnson & Johnson COVID-19 Booster, Administered Six Months After Two-Dose Regimen of BNT162b2, Shows Substantial Increase in Antibody and T-cell Responses – Johnson & Johnson Enters into Agreement to Provide its Single-Shot COVID-19 Vaccine for the World’s Most Vulnerable People through Novel Humanitarian Buffer – Johnson & Johnson COVID-19 Vaccine Demonstrates 85 Percent Effectiveness against Hospitalization in South Africa when Omicron was Dominant Medical Devices • Regulatory Decisions: – U.S. FDA Approves New MENTOR® MemoryGel BOOST™ Breast Implant2 • Other: – Johnson & Johnson Medical Devices Companies Announces Strategic Partnership with Microsoft to Further Enable its Digital Surgery Solutions2 Enterprise • Other – Johnson & Johnson Announces Plans to Accelerate Innovation, Serve Patients and Consumers, and Unlock Value through Intent to Separate Consumer Health Business – Johnson & Johnson Appoints Senior Leaders to Executive Committee – Johnson & Johnson announces significant progress towards its climate goals – 100% renewable electricity for all sites in the United States, Canada and Europe by 2023 17 1 These developments and all other news releases are available online in the Investors section of the company’s website at news releases, as well as www.factsabouttalc.com, www.factsaboutourprescriptionopioids.com, and www.LTLManagementInformation.com 2 Subsequent to the quarter -- 17 of 33 -- Joseph J. Wolk Executive Vice President, Chief Financial Officer -- 18 of 33 -- Creating Two Global Leaders That Will Advance Our Mission Pursue More Targeted Business Strategies and Accelerate Growth Carry on Johnson & Johnson’s Legacy of Putting the People We Serve First Deliver Improved Health Outcomes for Patients and Consumers Create Opportunities for Our Talented Global Team We are taking a bold, Credo-based action to evolve our business in order to provide value to our stakeholders today, tomorrow, and in the decades ahead 19 -- 19 of 33 -- Capital Allocation Strategy Capital Allocation Organic growth business needs Free cash flow1 Priorities are clear and remain unchanged Competitive dividends Share repurchases HIGHER PRIORITY LOWER PRIORITY Investment in M&A Dollars in Billions Q4 2021 Cash and Marketable Securities $32 Debt ($34) Net Debt ($2) Free Cash Flow1,2 ~$20 Full Year 2021: $14.7B invested in R&D $11.0B in dividends paid to shareholders Note: values may have been rounded 1 Non-GAAP measure; cash flow from operations less CAPEX 2 Estimated as of January 25, 2022. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings 20 -- 20 of 33 -- 21 2022 Sales Guidance Consumer Health • Expect some continued COVID-19 headwinds, but anticipate overall market recovery to improve throughout the year • Assume continued competitive momentum as year progresses with value maximization of significant prior year launches Medical Devices • Anticipate external supply constraints to continue and estimate the majority of impact will be in first half of 2022, primarily the first quarter, in Skin Health/Beauty • Expect the second half of 2022 to outperform the first half Pharmaceutical 1 Non-GAAP measure; excludes acquisitions and divestitures 3 Euro Average Rate: January 2022 = $1.14 2 Non-GAAP measure; excludes the impact of translational currency Note: Percentages may be rounded Phasing Considerations by Segment • Anticipate another year of above- market growth • Relatively consistent growth across all four quarters January (Base Business) January (Incl. COVID-19 Vaccine) Comments Adjusted Operational Sales1,2 6.5% - 7.5% 7.0% - 8.5% Estimated COVID-19 Vaccine sales of $3.0B - $3.5B Operational Sales2 $97.3B - $98.3B 6.5% - 7.5% $100.3B - $101.8B 7.0% – 8.5% Estimated Reported Sales3 $95.9B - $96.9B 5.0% - 6.0% $98.9B - $100.4B 5.5% – 7.0% -- 21 of 33 -- 2022 P&L Guidance 1 Non-GAAP measure; excludes acquisitions and divestitures 4 Non-GAAP measure; excludes intangible amortization expense and special items Note: Percentages may be rounded 2 Non-GAAP measure; excludes the impact of translational currency 5 Sales less: COGS, SM&A and R&D expenses 3 Euro Average Rate: January 2022 = $1.14 6 Comment updated 1-26-2022 January (Incl. COVID-19 Vaccine) Comments Adjusted Operational Sales1,2 7.0% - 8.5% Midpoint of 7.7% Operational Sales2 $100.3B - $101.8B 7.0% – 8.5% Estimated COVID-19 Vaccine sales of $3.0B - $3.5B Estimated Reported Sales 3 $98.9B - $100.4B 5.5% – 7.0% FX ($1.4B) or (1.5%) impact Midpoint of $99.6B or 6.2% Adjusted Pre-Tax Operating Margin4,5 ~50 bps improvement OPEX leverage partially offset by inflationary pressures in COGS Net Other Income4 $1.2 - $1.4 billion Generally consistent with 2021 levels Net Interest Expense / (Income) $0 - $100 million Effective Tax Rate4 15.5% - 16.5% Geographic mix and the impact of 2022 OUS tax legislation changes6 Adjusted EPS (Operational)2,4 $10.60 - $10.80 8.2% - 10.2% Midpoint of $10.70 or 9.2% Adjusted EPS (Reported)3,4 $10.40 - $10.60 6.1% - 8.2% FX ($0.20) or (2.1%) impact Midpoint of $10.50 or 7.1% 22 -- 22 of 33 -- Joaquin Duato Chief Executive Officer 4TH QUARTER 2021 EARNINGS -- 23 of 33 -- 24 -- 24 of 33 -- -- 25 of 33 -- -- 26 of 33 -- -- 27 of 33 -- -- 28 of 33 -- Q&A Joseph J. Wolk Executive Vice President, Chief Financial Officer Jessica Moore Vice President, Investor Relations Chief Executive Officer Joaquin Duato -- 29 of 33 -- -- 30 of 33 -- OTC $5,227 Skin Health/Beauty $4,541 Oral Care $1,645 Baby Care $1,566 Women's Health $917 Wound Care/Other $739 $14,635 4.1%, 2.8% WW Sales $MM ■ Reported Growth ■ Operational Growth1 Consumer Health Highlights – Full Year 2021 Solid growth across all regions primarily driven by OTC 31 Key Drivers of Operational Performance1 OTC • Growth driven by increased U.S. adult & pediatric fever and allergy incidences, Cough, Cold, & Flu and Digestive Health category recovery, continued momentum in NICORETTE, China MOTRIN recovery, ORSL HCP recommendations, and U.S. and Korea Adult TYLENOL increased consumption for vaccination symptom relief Skin Health/ Beauty • Growth driven by COVID-19 recovery, strong performance of NEUTROGENA and AVEENO, and e-commerce acceleration partially offset by divestitures of DR. CI LABO – Sedona and ROC Oral Care • Decline driven by floss divestiture and U.S. external supply constraints partially offset by market growth in the U.S. along with strong performance in ASPAC due to successful brand building and promotional campaigns Baby Care • Growth driven by AVEENO ASPAC e-commerce strength, innovation and COVID-19 recovery, coupled with LATAM price actions and share gains Women’s Health • Growth driven by COVID-19 recovery, price actions, and strong brand building in ASPAC partially offset by flooding negatively impacting EMEA Wound Care/Other • Growth driven by strong performance in BAND-AID® Brand Adhesive Bandages in the U.S. partially offset by product discontinuations and competitive pressures in ASPAC Adjusted Operational Sales2: WW 3.8%, U.S. 3.0%, Int’l 4.4% Additional 2020 shipping days negatively impacted WW growth by ~1% Reported: WW 4.1%, U.S. 2.4%, Int’l 5.6% Operational1: WW 2.8%, U.S. 2.4%, Int’l 3.1% 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website 2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website Note: Values may not add due to rounding 8.4%, 6.2% 1.8%, 1.9% 2.6%, 1.2% 3.2%, 2.9% 0.2%, (1.2)% 2.0%, 1.0% -- 31 of 33 -- Key Drivers of Operational Performance1 Immunology • Growth driven by continued strong uptake of STELARA in Crohn’s Disease and Ulcerative Colitis, strength of TREMFYA in Psoriasis and uptake in Psoriatic Arthritis • REMICADE decline due to biosimilar competition Infectious Diseases • Growth driven by the contribution of the COVID-19 vaccine • Partially offset by increased competition for PREZISTA/PREZCOBIX/REZOLSTA and PREZISTA OUS LOE Neuroscience • Paliperidone long-acting injectables growth due to strength of INVEGA SUSTENNA/XEPLION and INVEGA TRINZA/TREVICTA from new patient starts and persistency, and the launch of INVEGA HAFYERA Oncology • DARZALEX increase driven by continued strong market growth and share gains in all regions and solid uptake of the subcutaneous formulation launched in 2020 • IMBRUVICA growth primarily driven by market and continued share leadership, partially offset by COVID-19 related market dynamics including continued delays in new patient starts as well as competitive pressures • Continued strong global launch uptake of ERLEADA Cardiovascular/ Metabolism/ Other (CVM/Other) • Decline driven by lower sales of PROCRIT/EPREX due to biosimilar competition • INVOKANA/INVOKAMET decline due to continued share erosion Pulmonary Hypertension (PH) • Growth driven by strong sales of OPSUMIT and UPTRAVI due to continued share gains and market growth Adjusted Operational Sales2: WW 13.6%, U.S. 8.6%, Int’l 20.2% Additional 2020 shipping days negatively impacted WW growth by ~1%Immunology $16,750 Infectious Diseases $5,861 Neuroscience $7,011 Oncology $14,548 CVM/Other $4,460 PH $3,450 $52,080 14.3%, 13.1% WW Sales $MM ■ Reported Growth ■ Operational Growth1 Pharmaceutical Highlights – Full Year 2021 32 Reported: WW 14.3%, U.S. 8.6%, Int’l 21.6% Operational1: WW 13.1%, U.S. 8.6%, Int’l 18.8% 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website 2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website Note: Values may not add due to rounding (8.6)%, (9.6)% 9.6%, 9.2% 17.6%, 16.0% 7.1%, 5.9% 64.0%, 62.5% 11.3%, 10.2% 10th consecutive year of above-market performance driven by double-digit growth in key products -- 32 of 33 -- Orthopaedics $8,588 Surgery $9,812 Vision $4,688 Interventional Solutions $3,971 $27,060 17.9%, 16.2% WW Sales $MM ■ Reported Growth ■ Operational Growth1 Medical Devices Highlights – Full Year 2021 Growth primarily driven by COVID-19 related market recovery, commercial initiatives and innovation 33 Reported: WW 17.9%, U.S. 14.9%, Int’l 20.6% Operational1: WW 16.2%, U.S. 14.9%, Int’l 17.3% Key Drivers of Operational Performance1 Interventional Solutions • Market recovery, success of new products (VIZIGO and CARTO V7) and commercial strategies continuing to enhance global leadership Orthopaedics • Hips: Growth reflects market recovery combined with continued strength of our portfolio including the ACTIS stem and enabling technologies – KINCISE & VELYS Hip Navigation • Trauma: Growth reflects global market recovery and uptake of new products including Cannulated Compression Headless Screws, Advanced Nailing Systems and FIBULINK • Knees: Growth primarily driven by procedure recovery and new product introductions • Spine, Sports & Other: Growth driven primarily by COVID-19 market recovery and new products in Spine and Sports • Spine: WW: ~+4%, U.S.: ~+3%, OUS: ~+5% Surgery • Advanced: • Endocutters: ~+16% Driven by market recovery and new products (ECHELON Staple Line Reinforcement) offsetting competitive pressure in the U.S. • Biosurgery: ~+19% Market recovery and share expansion driven by success of newer products (VISTASEAL and SURGICEL POWDER) and ASPAC market expansion • Energy: ~+18% Primarily due to market recovery, new products and market expansion offsetting competitive pressures in the U.S. • General: Growth primarily driven by market recovery and continued strength of the Suture portfolio Vision • Contact Lenses/Other: Growth driven primarily by market recovery and market share gains from new products (ACUVUE OASYS Multifocal and ACUVUE DEFINE Fresh). • Surgical: Growth primarily due to market recovery and market share gains from uptake of recently launched products (TECNIS EYHANCE and TECNIS SYNERGY) Adjusted Operational Sales2: WW 16.8%, U.S. 15.3%, Int’l 18.3% Additional 2020 shipping days negatively impacted WW growth by ~1% 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website 2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website Note: Values may not add due to rounding; Beginning in the fiscal first quarter of 2022, the Medical Devices segment will be referred to as the MedTech segment 30.4%, 28.2% 19.6%, 19.0% 10.6%, 9.1% 19.2%, 17.0% -- 33 of 33 --